Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. The firm's proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/16/21 | $60,000,000 | Series C |
Arboretum Ventures New Enterprise Associates Pavilion Capital Temasek Vertex Growth Vertex Ventures WTT Investment Ltd | undisclosed |
